Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq(TM) (asfotase alfa) Sustained for at least Five Years

Business Wire October 12, 2015

Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015

Business Wire October 12, 2015

Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Business Wire October 2, 2015

Healthcare Sector Stocks under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences and Cytori Therapeutics

PR Newswire September 29, 2015

Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Data on Strensiq(TM) (asfotase alfa) in Children with Hypophosphatasia (HPP) Treated for Five Years

Business Wire September 16, 2015

New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma(TM) (sebelipase alfa) in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D)

Business Wire September 9, 2015

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire September 9, 2015

Alexion Receives Notification of PDUFA Date Extension for Kanuma(TM) (sebelipase alfa)

Business Wire September 4, 2015

Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference

Business Wire September 3, 2015

European Commission Grants Marketing Authorization for Strensiq(TM) (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)

Business Wire September 1, 2015

European Commission Grants Marketing Authorization for Kanuma(TM) (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)

Business Wire September 1, 2015

Alexion Reports Second Quarter 2015 Results

Business Wire July 30, 2015

Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015

Business Wire July 13, 2015

Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)

Business Wire July 6, 2015

Alexion Receives CHMP Positive Opinions for Strensiq(TM) (asfotase alfa) and Kanuma(TM) (sebelipase alfa) in the European Union

Business Wire June 26, 2015

Alexion Completes Acquisition of Synageva

Business Wire June 23, 2015

Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer

Business Wire June 22, 2015

Alexion to Present at Investor Conferences

Business Wire June 2, 2015

Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion's Pending Acquisition of Synageva

Business Wire May 29, 2015

SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

PR Newswire May 8, 2015